secondary cardiovascular prevention
Secondary prEvention of CardiovascUlaR disease
secondary prevention of cardiovascular events
Cardiovascular diseases
elderly population
cardiovascular causes
secondary endpoints
European population
population level
established efficacy of cardiovascular medications
Elderly trial
treatment of chronic diseases
FDC intervention
suboptimal adherence
suboptimal clinical benefit
polypill
deaths
large population of older adults eligible
main cause of death
potential benefit
main objective
comprehensive treatment strategy
coronary heart disease
drafting of clinical guidelines
intermediate measures of risk factor control
nonfatal myocardial infarction
Hungary
Spain
Italy
France
stroke
survival of patients
CVD
fixed dose combination
subjects
Poland
lipids
Germany
recommendations
effectiveness
primary reason
different countries
major challenges
revascularisation
stakeholders
hospitalisation
strategies
regional differences
blood pressure
standard therapy
useful guidance
Czech Republic
half
components
pharmacoeconomic impact
overall ageing
years old
reference framework
five-year project
outcomes
findings
conclusions